CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


sodium chloride 0.9%Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug587 Clofazimine Wiki 1.00
drug1222 Interferon beta-1b Wiki 1.00
drug2434 TRV027 Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D020141 Hemostatic Disorders NIH 0.30
D001778 Blood Coagulation Disorders NIH 0.30

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001928 Abnormality of coagulation HPO 0.30

There is one clinical trial.

Clinical Trials


1 Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19

To determine whether the coagulopathy associated with COVID-19 infection is driven by overactivation of the renin angiotensin system (RAS)

NCT04419610 COVID Biological: TRV027 Other: sodium chloride 0.9%
MeSH:Hemostatic Disorders Blood Coagulation Disorders
HPO:Abnormality of coagulation Abnormality of the coagulation cascade

Primary Outcomes

Description: Mean change from baseline D-dimer at day 8 following administration of TRV027 or placebo.

Measure: Coagulopathy associated with COVID-19

Time: Day 1 and Day 8

Secondary Outcomes

Description: Absolute D-Dimer - (Fibrin Equivalent units)

Measure: Markers of dysregulation of coagulation system

Time: Day 1 and Day 8

Description: platelet count (E9 /L)

Measure: Markers of dysregulation of coagulation system

Time: Day 1, 3, Day 5 and Day 8

Description: aPTT (Activated Partial Thromboplastin time) - seconds

Measure: Markers of dysregulation of coagulation system

Time: Day 1, 3, Day 5 and Day 8

Description: INR - (calculated as a ratio from aPTT)

Measure: Markers of dysregulation of coagulation system

Time: Day 1, 3, Day 5 and Day 8

Description: fibrinogen (g/L)

Measure: Markers of dysregulation of coagulation system

Time: Day 1, 3, Day 5 and Day 8

Description: Ferritin Ug/mL

Measure: Markers of dysregulation of coagulation system

Time: Day 1, 3, Day 5 and Day 8

Description: Plasma Renin Mass and activity (ng/ml/h)

Measure: Markers of dysregulation of RAS

Time: Day 3, Day 5 and Day 8

Description: Total bilirubin (umol/L)

Measure: Markers of Haemolysis/inflammation

Time: Day 1, 3, Day 5 and Day 8

Description: LDH u/L

Measure: Markers of Haemolysis/Inflammation

Time: Day 3, Day 5 and Day 8

Description: Haptoglobin g/L

Measure: Markers of Haemolysis/inflammation

Time: Day 1, 3, Day 5 and Day 8

Description: Pro-calcitonin ug/L

Measure: Markers of Inflammation (bacterial sepsis)

Time: day 1, 3, 5 and 8

Description: Creatinine (umol/L)

Measure: Markers of organ dysregulation - kidney

Time: Day 1, 3, Day 5 and Day 8

Description: BNP (B-type natriuetic Peptide) ng/L

Measure: Markers of dysregulation of cardiovascular system

Time: Day 1, 3, Day 5 and Day 8

Description: Troponin ng/L

Measure: Markers of dysregulation of cardiovascular system

Time: Day 1, 3, Day 5 and Day 8

Description: glucose mmol/L

Measure: marker of dysregulation of endocrine system

Time: Day 1, 3, Day 5 and Day 8


Related HPO nodes (Using clinical trials)